Maynard Um
-
-
-
-
-
-
-
Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens
-
-
-
-
-
-
-
Mirum reports volixibat meets primary endpoint in cholangitis study
-
-
-
-
-
-
-
Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens
-
-
-
-
-
-
-
RBC Capital Defending Mirum Pharmaceuticals (MIRM) Amid 15% Drop: 'Buying Opportunity Ahead of Multiple De-risked Catalysts'
-
-
-
-
-
-
-
TD Cowen on Mirum Pharmaceuticals (MIRM): 'Remain at Buy for base business and pipeline'
-
-
-
-
-
-
-
Mirum Pharmaceuticals (MIRM) PT Raised to $110 at Raymond James
-
-
-
-
-
-
-
Mirum presents liver disease drug data at AASLD conference
-
422,929 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

